Home > News > 29/Reprogramming to prevent progressive pacemaker remodelling
Read Time: 2 mins

29/Reprogramming to prevent progressive pacemaker remodelling

Published Online: October 2nd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr29
Authors: MF Paton (Presenting Author) - University of Leeds, Leeds, UK; J Gierula - University of Leeds, Leeds, UK; JE Lowry - University of Leeds, Leeds, UK; K Bose Rosling - University of Leeds, Leeds, UK; CED Saunderson - University of Leeds, Leeds, UK; IM Drozd - University of Leeds, Leeds, UK; DA Cairns - University of Leeds, Leeds, UK; RM Cubbon - University of Leeds, Leeds, UK; MT Kearney - University of Leeds, Leeds, UK; KK Witte - University of Leeds, Leeds, UK
Quick Links:
Article Information

Background: There are over 740 bradycardia pacemaker patients per million in Western Europe. Pacemakers are a safe and effective treatment to bradycardia to increase longevity and improve quality of life. Cross-sectional and retrospective studies have suggested left ventricular systolic dysfunction (LVSD) and heart failure (HF) are common in the pacemaker population. Personalised pacemaker programming in an observational cohort has successfully reduced pacing requirements leading to improved left ventricular (LV) function without affecting quality of life. No randomised trial has yet explored these effects.

Methods: This was a randomised double-blind parallel study of personalised reprogramming versus standard care on ventricular pacing burden, LV function, and pacemaker longevity. The study was approved by ethical committee and registered on clinicaltrials.gov. Patients were eligible if they had a bradycardia pacemaker for indications other than third degree heart block and adequate echocardiographic imaging. All participants gave written consent, received a transthoracic echocardiogram, pacemaker interrogation, blood draw, clinical examination and had a clinical history taken alongside quality of life assessment. Participants were contacted to ensure acceptability and safety of reprogramming at 1 week by a blinded healthcare professional, and followed up at 6 months.

Results: One hundred patients were recruited and assigned 1:1 to reprogramming intervention or standard care. Study groups were well matched for age, ventricular pacing burden, and LV function (as measured by ejection fraction). Personalised reprogramming involved assessment and manipulation of the base rate (44%), sleep, rest or hysteresis rates (68%), mode (8%), rate-response (38%), atrioventricular search (4%), autocapture (36%), lead outputs (74%) and electrogram storage (10%) as appropriate and based upon a previously published reprogramming protocol. Eight patients withdrew due to illness or the onset of a life-threatening co-morbidity, 1 patient was upgraded to a biventricular device. Seventy-one participants were male with a mean age of 75.8 years, right ventricular (RV) pacing burden of 36.2% and ejection fraction of 49.7%. Intervention compared to usual care significantly reduced RV pacing burden (–6.5 ± 1.8% versus
–0.21 ± 1.7%; p<0.01), improved ejection fraction (+2.1 ± 6.9% versus –0.70 ± 5.6%; p=0.03), and preserved minimum battery longevity by approximately 6 months (–1.4 ± 7.8 months versus
–7.3 ± 12.5 months; p<0.01). 1 patient returned with worsening symptoms but was subsequently upgraded due to deteriorating heart failure. Quality of life analyses are underway.

Conclusion: Personalised pacemaker reprogramming, even in the era of RV pacing avoidance algorithms, can reduce unnecessary RV pacing, improve left ventricular ejection fraction and significantly preserve battery life in pacemaker patients.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
43/Cardiac tamponade as a complication of transseptal puncture: associations and operatordependent variables during left atrial ablation at Barts Heart Centre
E Maclean (Presenting Author) - St Bartholomew’s Hospital, London; K Mahtani - St Bartholomew’s Hospital, London; C Butcher - St Bartholomew’s Hospital, London; N Ahluwalia - St Bartholomew’s Hospital, London; M Finlay - St Bartholomew’s Hospital, London; S Honarbakhsh - St Bartholomew’s Hospital, London; A Creta - St Bartholomew’s Hospital, London; A Chow - St Bartholomew’s Hospital, London; V Sawhney - St Bartholomew’s Hospital, London; V Ezzat - St Bartholomew’s Hospital, London; MJ Earley - St Bartholomew’s Hospital, London; M Dhinoja - St Bartholomew’s Hospital, London; S Sporton - St Bartholomew’s Hospital, London; MD Lowe - St Bartholomew’s Hospital, London; PD Lambiase - St Bartholomew’s Hospital, London; F Khan - St Bartholomew’s Hospital, London; SY Ahsan - St Bartholomew’s Hospital, London; RJ Hunter - St Bartholomew’s Hospital, London; RJ Schilling - St Bartholomew’s Hospital, London; O Sega - St Bartholomew’s Hospital, London Read Time: 2 mins

European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr43

Introduction: Cardiac tamponade is a high morbidity complication of transseptal puncture (TSP). We examined the incidence and predictors of TSP-related cardiac tamponade (TRCT) for all patients undergoing left atrial ablation at our centre from 2016-2020. Methods: Patient and procedural variables were extracted retrospectively. Cases of cardiac tamponade were scrutinised to adjudicate TSP culpability. Adjusted multivariate […]

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72